[EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
申请人:CADILA HEALTHCARE LTD
公开号:WO2009087649A1
公开(公告)日:2009-07-16
The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS
申请人:INVENTIVA
公开号:US20170066717A1
公开(公告)日:2017-03-09
The invention relates to compounds of formula (I).
where R, R
1
, R
2
, n, A and Cy have the meanings indicated in the description.
The compounds of formula (I) are Nurr-1 modulators.
Nitrogen-coordinated cobalt nanocrystals for oxidative dehydrogenation and hydrogenation of N-heterocycles
作者:Yue Wu、Zheng Chen、Weng-Chon Cheong、Chao Zhang、Lirong Zheng、Wensheng Yan、Rong Yu、Chen Chen、Yadong Li
DOI:10.1039/c9sc00475k
日期:——
positive charge on the Co surface, thereby promoting the reaction. In contrast, cobalt nanocrystals supported by pristine carbon (Co NCs/C) proved to be inactive for oxidative dehydrogenation, owing to the lack of nitrogen. Moreover, in Co NCs/N-C, the N-doped graphitized carbon formed a protective layer for Co NCs, which preserved the active valence of Co species and prevented the catalyst from leaching.
赋予非贵金属通常具有贵金属的高催化活性是替代贵金属的核心但具有挑战性的目标。为此,我们利用氮的配位效应,制备了氮掺杂石墨化碳稳定的钴纳米晶(Co NCs/NC)。所获得的Co NC/NC催化剂在极其温和的条件下对N-杂环的氧化脱氢及其逆加氢过程表现出非凡的性能。即使在室温(25℃)下,氧化脱氢也能实现近乎定量的转化,这归因于氮的配位效应:Co-N的相互作用在Co表面诱导部分正电荷,从而促进反应。相比之下,由于缺乏氮,由原始碳支撑的钴纳米晶体(Co NCs/C)被证明对于氧化脱氢没有活性。此外,在Co NCs/NC中,N掺杂的石墨化碳形成了Co NCs的保护层,保留了Co物种的活性价态并防止催化剂浸出。结果发现,催化剂经过5次再生循环后仍保持优异的催化活性;相比之下,其对应的氧化钴 (CoO x /NC) 几乎没有活性。至于其机制,电子顺磁共振(EPR)分析揭示了脱氢过程中超氧阴离子自由基的
4-heterocyclyl-substituted quinazoline derivatives, processes for their
申请人:Pfizer Inc.
公开号:US05736534A1
公开(公告)日:1998-04-07
This invention relates to certain 4-aminoquinazolines and the pharmaceutically acceptable salts and stereoisomers thereof, the formula whereof are described herein. The compounds are useful for the treatment of hyperproliferative diseases, particularly as anti-cancer agents.